MELBOURNE, AUSTRALIA – 04 October 2023 – CSL’s Research Acceleration Initiative (RAI) continues to expand its reach with seven medical researchers awarded new RAI partnerships, including up to an AU$500,000 investment in each program over two years, to fast-track the discovery of innovative biotherapies to address unmet medical needs.
The CSL Research Acceleration Initiative establishes partnerships between CSL and global research organisations to progress discoveries towards real-world treatments and accelerate the commercialisation of promising discovery programs. In addition to creating long-term mutual partnerships to further innovation, the initiative includes funding as well as access to CSL R&D experts.
- Laurent , Institute of Cardiovascular and Metabolic Diseases (I2MC), IHU HealthAge, INSERM
Dr Martinez is developing a novel class of therapeutic candidates for vascular diseases including stroke. If successful, these could be given to patients on top of existing treatments to provide significant additional benefit.
Borgel and Dr Saller are developing therapeutic nanobodies for the prevention and treatment
- Research Director INSERM / University of Toulouse
- Assoc Prof.
Assoc Prof. Tan Meng How will research novel methods, utilising DNA repair proteins, to enhance insertional gene editing in human cells.
Prof. Laurenti will investigate mRNA-based solutions to minimise the loss of haematopoietic stem cell (HSC) function occurring during an ex vivo gene therapy protocol. This could drive robustness of gene therapy product cell manufacture, and ultimately lead to improved outcomes for patients.
- Philipps-Universität Marburg, Germany
Prof. Leon Schulte will investigate the targeting of long non-coding RNAs (lncRNA) to enable precision-interventions in misguided immune-circuits during systemic inflammatory response-syndrome (SIRS), thus aiming to improve the survival rate of affected patients.
Dr Marthe D’Ombrain, CSL’s Head of Global Research Innovation said, “Through our Global Research Acceleration Initiative, we can tap into and support research innovation happening in all corners of the world. Excitingly, this last tranche of RAI awardees includes a new partnership in Asia, and another in the UK which is a first for the expanding initiative, and reflects CSL’s intent to further partner with world-class researchers around the world.
“Europe continues to be an important base for partnering for CSL and reflects the high calibre of research occurring across the continent. We look forward to collaborating with our new partners to support the development of their exciting discoveries”.
These Global RAI awardees’ research addresses important unmet medical needs in several of CSL’s therapeutic areas, which include immunology, nephrology and transplant, respiratory, hematology, cardiovascular and metabolic disease, and vaccines.
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 30,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL.
For more information about CSL, visit www.CSL.com.
# # #
Mobile: +61 449 884 603